Skip to main content
. Author manuscript; available in PMC: 2023 Dec 12.
Published in final edited form as: J Hypertens. 2023 Mar 3;41(5):751–758. doi: 10.1097/HJH.0000000000003396

Table 2.

Model-based means and estimated differences in BP control and BP-related process metrics across quarters, Q4-2017 – Q1-2020

Quarter 1 Quarter21 Quarter 3 Quarter 4 Overall

BP Metric Mean (SD) Δ Estimate
(95% CI)
Mean (SD) Δ Estimate
(95% CI)
Mean (SD) Δ Estimate
(95% CI)
Mean (SD) Δ Estimate
(95% CI)
P-Value

% BP Control (<140/<90 mmHg)
 Unadjusted model2 60.71 (2.59) −1.07 (−1.27, −0.87) 61.79 (2.57) 0 (Ref) 62.25 (2.55) 0.46 (0.21, 0.72) 61.51 (2.57) −0.27 (−0.72, 0.18) <.001
 Adjusted model 55.72 (2.40) −3.88 (−13.42, 5.65) 59.61 (3.89) 0 (Ref) 61.62 (5.43) 2.02 (−1.41, 5.45) 58.38 (1.88) −1.23 (−8.38, 5.93) 0.010
% Improvement in BP
 Unadjusted model2 29.22 (1.01) −2.73 (−3.52, −1.93) 31.95 (0.90) 0 (Ref) 29.88 (0.79) −2.07 (−2.49, −1.65) 28.93 (0.75) −3.01 (−3.60, −2.43) <.001
 Adjusted model 24.61 (1.61) −2.41 (−5.89, 1.07) 27.02 (1.78) 0 (Ref) 24.72 (2.28) −2.29 (−3.94, −0.65) 24.34 (1.40) −2.67 (−5.28, −0.07) <.001
% Medication Intensification
 Unadjusted model2 10.52 (0.54) 0.25 (−0.03, 0.53) 10.27 (0.59) 0 (Ref) 9.73 (0.60) −0.54 (−0.73, −0.35) 10.23 (0.58) −0.04 (−0.34, 0.26) 0.005
 Adjusted model 14.29 (1.65) 1.50 (−1.65, 4.64) 12.79 (1.59) 0 (Ref) 12.05 (1.89) −0.74 (−1.73, 0.25) 13.92 (1.60) 1.12 (−1.45, 3.70) 0.240
Average SBP Reduction after Med Intensification (mmHg)
 Unadjusted model2 15 (0.22) −0.73 (−1.01, −0.44) 16 (0.23) 0 (Ref) 15 (0.28) −0.89 (−1.19, −0.58) 14 (0.25) −1.46 (−1.76, −1.16) <.001
 Adjusted model 10 (0.38) −1.82 (−2.71, −0.94) 12 (0.37) 0 (Ref) 12 (0.57) −0.17 (−0.73, 0.38) 10 (0.37) −2.40 (−3.15, −1.65) <.001
1

Quarter 2 was used as reference to estimate differences between quarters

2

Unadjusted model: Quarter Year only

Adjusted model: Unadjusted model+Race/Ethnicity+Sex+Age+Diabetes+HF+CAD+Average Temperature